Artificial valve

Information

  • Patent Grant
  • 7081131
  • Patent Number
    7,081,131
  • Date Filed
    Tuesday, June 22, 2004
    20 years ago
  • Date Issued
    Tuesday, July 25, 2006
    18 years ago
Abstract
Method and apparatus implementing and using techniques for controlling flow in a body lumen, including use of an implantable medical device. The device includes a membrane implantable in a body lumen and invertibly deformable between a first position and a second position. The membrane is invertible in response to the direction of fluid flow through the lumen and can be deformable by fluid flow in the body lumen.
Description
FIELD OF THE INVENTION

This invention relates to medical devices for use in a body lumen.


BACKGROUND

A venous valve functions to prevent retrograde flow of blood and allow only antegrade flow of blood to the heart. Referring to FIG. 1A, a healthy venous valve 12 is illustrated in a vessel 10. The valve is bicuspid, with opposed cusps 14. In the closed condition, the cusps 14 are drawn together to prevent retrograde flow (arrow 16) of blood. Referring to FIG 1B, if the valve is incompetent, the cusps 14 do not seal properly and retrograde flow of blood occurs. Incompetence of a venous valve is thought to arise from at least the following two medical conditions: varicose veins and chronic venous insufficiency.


SUMMARY

This invention relates to medical devices for use with a body lumen. In one aspect, the invention features a medical device including a membrane implantable in a body lumen and invertibly deformable between a first position and a second position. The membrane is invertible in response to the direction of fluid flow through the lumen and can be deformable by fluid flow in the body lumen. The membrane can be invertible relative to a radial direction of the body lumen. The membrane can be reversibly deformable between the first position and the second position.


Implementations can include one or more of the following. The membrane can define a portion of a cone, and can include an anchoring element adjacent a vertex of the cone. The membrane can include an anchoring element configured to embed within the body lumen, or alternatively configured to penetrate through the body lumen. The anchoring element may be, for example, a loop or a barb. The membrane can be formed of a polymer, for example, a polyurethane, polyethylene or fluoroplastic.


In another aspect, the invention features a medical system. The system includes multiple membranes, each membrane implantable in a body lumen and invertibly deformable between a first position and a second position. Each membrane is invertible in response to the direction of fluid flow through the lumen.


Implementations of the system can include one or more of the following. The membranes can be symmetrically implantable in the body lumen. Each membrane can be invertible relative to a radial direction of the body lumen and can be deformable by fluid flow in the body lumen. At least one membrane can be reversibly deformable between the first position and the second position. At least one membrane can define a portion of a cone and can include an anchoring element adjacent a vertex of the cone. At least one membrane can include an anchoring element configured to embed within the body lumen or alternatively configured to penetrate through the body lumen. The anchoring element can be, for example, a loop or a barb. At least one membrane can be formed of a polymer, for example, a polyurethane, polyethylene or fluoroplastic.


In another aspect, the invention features a method. The method includes positioning at least one membrane in a body lumen, each membrane invertibly deformable between a first position and a second position. Each membrane is invertible in response to the direction of fluid flow through the lumen.


Implementations of the method can include one or more of the following. The method can include positioning multiple membranes in the body lumen. The multiple membranes can be positioned symmetrically in the body lumen. The method can include penetrating an anchoring element of the at least one membrane through the body lumen or, alternatively, embedding an anchoring element of the at least one membrane into the body lumen.


In another aspect, the invention features a method of controlling flow in a body lumen. The method includes invertibly deforming a membrane between a first position and a second position, the membrane being invertible in response to the direction of fluid flow through the lumen. Implementations can include one or more of the following. The membrane in the second position and a portion of the body lumen can define a cavity. Deformation of the membrane can be relative to a radial axis of the body lumen. The membrane can be deformable by fluid flow in the body lumen. The membrane in the first position and the membrane in the second position can be approximately mirror images of each other. The method can further include invertibly deforming a plurality of membranes.


Embodiments may have one or more of the following advantages. One or more invertible membranes, which can function as artificial valve cusps, can be implanted at a treatment site using a catheter. As such, implantation is minimally invasive and avoids surgery and the possibility of the inherent complications. The membrane is fabricated from a polymer such as a polyurethane, polyethylene or fluoroplastic, which materials are more easily accessible than a natural tissue excised from an animal, and can be manufactured with consistency and efficiency that could be more difficult or more expensive using a natural tissue.


Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.





DESCRIPTION OF DRAWINGS


FIGS. 1A and 1B are illustrations of a venous valve and an incompetent venous valve, respectively.



FIGS. 2A, 2B, and 2C are partial perspective views of an embodiment of a valve cusp.



FIG. 3 is a cross-sectional view of the valve cusp of FIG. 2A, taken along line 33.



FIG. 4 is a cross-sectional view of the valve cusp of FIG. 2C, taken along line 44.



FIGS. 5A, 5B, 5C, 5D and 5E are schematic views of an embodiment of a method for implanting a valve cusp.



FIGS. 6A and 6B are partial perspective views of an embodiment of a valve cusp.



FIGS. 7A and 7B are partial perspective views of an embodiment of a valve cusp.



FIG. 8 is a cross-sectional view of the valve cusp of FIG. 7A, taken along line 88.



FIG. 9 is a cross-sectional view of the valve cusp of FIG. 7B, taken along line 99.



FIG. 10 is a partial perspective view of an embodiment of an anchoring element.



FIG. 11 is a partial perspective view of an embodiment of an anchoring element.





DETAILED DESCRIPTION

Referring to FIGS. 2A–2C through FIG. 4, a pair of artificial valve cusps 30 are illustrated positioned within a vessel 46, e.g., a vein. Cusps 30 can be positioned upstream or downstream relative to an incompetent venous valve, such as the valve shown in FIG. 1B. Each artificial valve cusp 30 includes at least one anchoring element 38 attached to an invertible portion 42, here, an approximately triangular, flexible membrane. Anchoring element 38 is generally configured to hold invertible portion 39 at a desired location in vessel 46. For example, anchoring element 38 can embed itself within a wall 44 of vessel 46, or penetrate through the wall to secure cusp 30 to the vessel. Invertible portion 42 is capable of deforming between a first position and a second position, e.g., between an opened condition and a closed position, in response to flow of body fluid in vessel 46 to allow or to reduce the flow in the vessel.


Referring particularly to FIG. 2A and FIG. 3, the cusps 30 are shown in a first position in which each cusp 30 forms an approximate semi-cone, such that an opening 50 is formed by the curved surfaces of the cusps 30. The opening 50 allows antegrade flow of a fluid through the vessel in the direction indicated by arrow 48. The membranes of invertible portions 42 are relatively thin and can conform closely to the vessel wall 44 to maximize the size of opening 50. However, each cusp 30 is also held slightly away from the wall 44 of the vessel 46 by the anchoring element 38, such that a gap 52 is formed between the invertible portion 42 and the wall 44.


Referring particularly to FIG. 2B, retrograde flow of fluid (arrows 51) in the vessel can accumulate in the gap 52 and exert pressure on the invertible portion 42 of the cusp 30. Since invertible portion 42 is flexible, it can deform under the exerted pressure and invert to form another approximate semi-cone, as shown in FIG. 2C. That is, each cusp 30 forming a first semi-cone in the first position can invert or flip relative to a radial axis of vessel 46 to form a second semi-cone that is approximately the mirror image of the first semi-cone. As the interior 32 of the second semi-cone accumulates retrograde flowing fluid, pressure is exerted on the interior of cusp 30, causing the cusp to move away from the wall 44 of the vessel. As a result, the space 53 between the two cusps 30 narrows, the size of opening 50 decreases, and fluid flow through the vessel and past the cusps is reduced (FIG. 4).


The cusps 30 can remain in the second position until antegrade fluid flow exerts sufficient pressure on the surface of cusps 30 opposite interior 32 and inverts the cusps to the first position. Thus, cusps 30 provide an artificial valve that automatically responds to the flow of fluid or pressure changes in vessel 46.



FIGS. 5A to 5E show one method of positioning cusps 30 at a treatment site in vessel 46 using a catheter 18 that may be delivered into the vessel 46 ercutaneously. The catheter 18 is generally adapted for delivery through the vessel 46, e.g., using a guidewire. Catheter 18 includes a long, flexible body having a central portion 21, and a retractable sheath 22 over the central portion. Referring particularly to FIG. 5B, a cross-sectional view of FIG. 5A taken along line 55, two grooves 25 are formed on either side of the central portion 21, and a push rod 28 is positioned inside each of the grooves 25. Each cusp 30 is positioned in a groove 25 in a compacted state and held in place by the retractable sheath 22 until delivery at the treatment site.


Catheter 18 can be delivered to the treatment site using endoprosthesis delivery techniques, e.g., by tracking an emplaced guidewire with central lumen 101. At the treatment site, the retractable sheath 22 is retracted proximally to form an opening 26 at the end of each groove 25. Referring particularly to FIG. 5C, push rods 28 are used to push each cusp distally toward the opening 26 to push the anchoring element 38 out of the opening 26. The cusps 30 are pushed out of the openings 26 until the anchoring elements 38 secure the cusps 30 to the wall 44 of the vessel 46. For example, the anchoring elements 38 can embed within the wall 44 or penetrate the wall 44 and secure to the exterior of the vessel 46.


After each cusp 30 is secured to the vessel 46, the retractable sheath 22 is retracted to fully expose the cusps 30 (FIG. 5D). The central portion 21 is then pulled proximally past the flexible (and deflectable) cusps 30 and retracted from the vessel 46 (FIG. 5E). The cusps 30, now secured to the wall 44, can deform between the first and second positions, as described above.


Cusps 30 are preferably made of a biocompatible material capable of reversible deformation as described above. Each cusp 30 can be formed from a thin, flexible material, such as a polyurethane, polyethylene or fluoroplastic, for example, polytetrafluoroethylene (PTFE). Invertible portion 42 can be formed of one or more materials. For example, invertible portion 42 may include an edge portion that is relatively more flexible or more compliant than another portion of the invertible portion to help the edges meet and seal when the cusps 30 are in the second position. Cusps 30 can include a radiopaque material, such as a polymer including a radiopacifier, e.g., tantalum metal or bismuth oxychloride, for positioning and monitoring the cusps.


Similarly, anchoring element 38 is preferably biocompatible. The anchoring element 38 can be formed of a relatively rigid material, such as a polymer having suitable hardness, for example, acrylonitrile-butadiene-styrene (ABS). Other materials can be used, such as metals (e.g., tantalum, tungsten or gold), alloys (e.g., stainless steel or Nitinol), and ceramics. Anchoring elements 38 can include a radiopaque material for positioning and monitoring cusps 30. The anchoring element can be embedded in the invertible portion or fixed to a surface of the invertible portion with, for example, adhesive.


OTHER EMBODIMENTS

In other embodiments, any number of cusps can be anchored to the wall 44 of the vessel 46 to function as a valve for preventing retrograde flow of blood through the blood vessel 46. Referring to FIGS. 6A and 6B, a single cusp 60 can be used. The cusp 60 can be 10 transported to the treatment site and anchored to the wall 44 of a vessel 46 in the same manner as described above using a catheter. In a first position, the cusp 60 forms an approximate semi-cone, with the edges 63 of the semi-cone facing the wall 44 opposite from where the cusp 60 is anchored to the wall 44. The interior of the cone forms a channel 64 allowing fluid flow past the cusp 60. The anchoring element 65 holds the cusp 30 slightly away from the wall 44 such that a gap 66 is formed between the cusp 60 and the wall 44. Retrograde flowing fluid can accumulate in the gap 66 and exert pressure on the cusp 60, deforming the cusp 60 and widening the gap 66 until the pressure on the cusp 60 inverts the cusp. Referring particularly to FIG. 6B, in an inverted position the cusp 60 forms an approximate cone with the wall 44 and accumulates retrograde flowing fluid in a sack 68 formed by the interior of the cone. Accumulated fluid can exert pressure on the cusp 60, causing the cusp 60 to move away from the wall 44. As a result, the space 66 between the cusp 60 and the wall 44 opposite the anchoring element narrows, until the cusp 60 touches the wall 44, in a second position as shown. In the second position, flow is reduced past the cusp 60 relative to the flow when the cusp 60 was in the first position. The cusp 60 remains in the second position until pressure exerted on the cusp 60 by the antegrade flow of fluid is sufficient to invert the cusp 60 to the first position.


Referring to FIGS. 7A–7B, three cusps 70a70c can be symmetrically secured to the wall 44 of a vessel 46 in a similar manner as described above. Referring particularly to FIG. 7A, the cusps 70a70care shown in first position that does not substantially impede flow of a fluid through the vessel 46. As shown in FIG. 8, the surfaces of the cusps 70a70cconform to the wall 44 of the vessel 46, allowing a substantial opening 72 for flow past the cusps 70a70c. Each cusp 70a70cis held away from the wall 44 by anchoring elements 71a71c, such that a gap 76 is formed between each cusp and the wall 44. As described above, retrograde flowing fluid accumulates in the gap 76 and exerts pressure on the cusp 70, causing the cusp to deform away from the wall 44, until the cusps invert.


Referring particularly to FIG. 7B, in an inverted position the interior of each cusp 70a70caccumulates retrograde flowing fluid. Exerting pressure on the cusps causes them to move toward one another, until the cusps 70a70cmeet in a second position and reduce flow past the cusps 70a70crelative to the when the cusps 70a70care in the first position. Referring to FIG. 9, the opening 72 is significantly reduced, thus restricting the fluid flow. The cusps 70a70cremain in the second position until pressure exerted on the cusps 70a70cby antegrade flow of fluid inverts the cusps to the first position.


Although the embodiments above describe a device having one to three cusps, any number of cusps can be used to prevent retrograde flow through a vessel. The cusps can be arranged symmetrically as shown, or can be arranged in any other configuration. Although the embodiments described above included cusps of similar size and configuration, cusps of differing sizes and configurations can be used in conjunction with each other.


The anchoring element can take a number of different forms that permit the end of the cusp to penetrate the wall of a blood vessel and restrain the end of the cusp from re-entering the vessel. For example, the anchoring element can be a barb element, as shown in the embodiments described above. Alternatively, the anchoring element can be a T-hook device 80 as shown in FIG. 10, wherein T-hook 80 penetrates the wall of a vessel and hooks 82 prevent the anchor from re-entering the vessel. In another embodiment, the anchoring element can define a loop 84, as shown in FIG. 11, wherein the looped end 86 prevents the anchor from re-entering the vessel.


In other embodiments, a cusp can include more than one anchoring element. A cusp can have other polygonal configurations. For example, a generally rectangular cusp can be secured to a vessel using two anchoring elements adjacent to two corners of the cusp. The cusp can form a semi-cylinder.


Other embodiments are within the scope of the following claims.

Claims
  • 1. A method comprising: positioning two or more frameless membranes in a body lumen, each membrane invertibly deformable between a first position and a second position,wherein at least one frameless membrane is invertible in response to the direction of fluid flow through the lumen relative to the membrane in the first position.
  • 2. The method of claim 1, including positioning the two or more frameless membranes symmetrically in the body lumen.
  • 3. The method of claim 1, wherein the two or more frameless membranes include an anchoring element, the method further including: penetrating the anchoring element through the body lumen.
  • 4. The method of claim 1, wherein the two or more frameless membranes include an anchoring element, the method further including: embedding the anchoring element of at least one frameless membrane into the body lumen.
  • 5. A medical system, comprising: a first frameless membrane;an elongate catheter including a central portion including a first groove surrounded by a retractable sheath, the first frameless membrane positioned in the first groove between the retractable sheath and the central portion; anda first push rod extending through the elongate catheter to the first groove to contact and extend the first frameless membrane from the elongate catheter.
  • 6. The medical system of claim 5, wherein the first frameless membrane includes an anchoring element, where the first push rod contacts the anchoring element of the first frameless membrane.
  • 7. The medical system of claim 6, wherein the first push rod pushes the anchoring element of the first frameless membrane from an opening of the first groove.
  • 8. The medical system of claim 7, wherein the retractable sheath fully retracts to expose the first frameless membrane.
  • 9. The medical system of claim 5, further including: a second frameless membrane including an anchoring element, wherein the central portion of the elongate catheter further includes a second groove, the second frameless membrane positioned in the second groove between the retractable sheath and the central portion; anda second push rod extending through the elongate catheter to the second groove to contact the anchoring element and extend the second frameless membrane from the elongate catheter.
  • 10. The medical system of claim 9, where the first frameless membrane and the second frameless membrane are invertibly deformable between a first position and a second position in response to a direction of a fluid flow past the first frameless membrane and the second frameless membrane.
  • 11. The medical system of claim 9, where each of the first frameless membrane and the second frameless membrane define a portion of a cone.
  • 12. The medical system of claim 11, where each of the first frameless membrane and the second frameless membrane include an anchoring element adjacent to a vertex of the cone.
  • 13. The medical system of claim 12, where the sheath retracts to provide a first opening and a second opening, where the anchoring element of the first frameless membrane is pushed by the first push rod through the first opening, and the anchoring element of the second frameless membrane is pushed by the second push rod through the second opening.
  • 14. The medical system of claim 13, where the anchoring element of the first frameless membrane and the second frameless membrane are formed of a relatively rigid material.
  • 15. The medical system of claim 13, where the anchoring element of the first frameless membrane and the second frameless membrane includes a loop.
  • 16. The medical system of claim 13, where the anchoring element of the first frameless membrane and the second frameless membrane includes a barb.
  • 17. The medical system of claim 9, where the first frameless membrane and the second frameless membrane are formed of a polymer.
  • 18. The medical system of claim 17, where the polymer is a material selected from a group consisting of polyurethanes, polyethylenes, and fluoroplastics.
  • 19. The medical system of claim 9, where the first groove and the second groove are positioned symmetrically in the elongate catheter.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 10/115,557, filed Apr. 3, 2002, now U.S. Pat. No. 6,752,828 issued Jun. 22, 2004, the specification of which is incorporated herein by reference.

US Referenced Citations (288)
Number Name Date Kind
3859392 Beermann et al. Jan 1975 A
3903548 Nakib Sep 1975 A
4218782 Rygg Aug 1980 A
4406022 Roy Sep 1983 A
4580568 Gianturco Apr 1986 A
4643732 Pietsch et al. Feb 1987 A
4851001 Taheri Jul 1989 A
4863467 Bokros Sep 1989 A
5024232 Smid et al. Jun 1991 A
5032128 Alonso Jul 1991 A
5080668 Bolz et al. Jan 1992 A
5147389 Lane Sep 1992 A
5156619 Ehrenfeld Oct 1992 A
5163953 Vince Nov 1992 A
5358518 Camilli Oct 1994 A
5360401 Turnland Nov 1994 A
5413599 Imachi et al. May 1995 A
5476471 Shifrin et al. Dec 1995 A
5607465 Camilli Mar 1997 A
5609598 Laufer et al. Mar 1997 A
5769780 Hata et al. Jun 1998 A
5810847 Laufer et al. Sep 1998 A
5855601 Bessler et al. Jan 1999 A
5919224 Thompson et al. Jul 1999 A
6015431 Thornton et al. Jan 2000 A
6027525 Suh et al. Feb 2000 A
6110201 Quijano et al. Aug 2000 A
6126686 Badylak et al. Oct 2000 A
6162245 Jayaraman Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6168619 Dinh et al. Jan 2001 B1
6200336 Pavenik et al. Mar 2001 B1
6241763 Drasler et al. Jun 2001 B1
6287334 Moll et al. Sep 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6315793 Bokros et al. Nov 2001 B1
6319281 Patel Nov 2001 B1
6328727 Frazier et al. Dec 2001 B1
6334873 Lane et al. Jan 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6458153 Bailey et al. Oct 2002 B1
6503272 Duerig et al. Jan 2003 B1
6508833 Pavenik et al. Jan 2003 B1
6572652 Shaknovich Jun 2003 B1
6602286 Strecker Aug 2003 B1
6666885 Moe Dec 2003 B1
6666886 Tranquillo et al. Dec 2003 B1
6669725 Scott Dec 2003 B1
6673109 Cox Jan 2004 B1
6676698 McGuckin, Jr. et al. Jan 2004 B1
6676702 Mathis Jan 2004 B1
6682558 Tu et al. Jan 2004 B1
6682559 Myers et al. Jan 2004 B1
6685739 DiMatteo et al. Feb 2004 B1
6692512 Jang Feb 2004 B1
6695866 Kuehn et al. Feb 2004 B1
6695878 McGuckin, Jr. et al. Feb 2004 B1
6709456 Langberg et al. Mar 2004 B1
6709457 Otte et al. Mar 2004 B1
6716241 Wilder et al. Apr 2004 B1
6716244 Klaco Apr 2004 B1
6719767 Kimblad Apr 2004 B1
6719784 Henderson Apr 2004 B1
6719786 Ryan et al. Apr 2004 B1
6719787 Cox Apr 2004 B1
6719788 Cox Apr 2004 B1
6719789 Cox Apr 2004 B1
6719790 Brendzel et al. Apr 2004 B1
6723038 Schroeder et al. Apr 2004 B1
6723122 Yang et al. Apr 2004 B1
6723123 Kazatchkov et al. Apr 2004 B1
6726715 Sutherland Apr 2004 B1
6726716 Marquez Apr 2004 B1
6726717 Alfieri et al. Apr 2004 B1
6730118 Spenser et al. May 2004 B1
6730121 Ortiz et al. May 2004 B1
6730122 Pan et al. May 2004 B1
6736845 Marquez et al. May 2004 B1
6736846 Cox May 2004 B1
6749630 McCarthy et al. Jun 2004 B1
6752813 Goldfarb et al. Jun 2004 B1
6752828 Thornton Jun 2004 B1
6755857 Peterson et al. Jun 2004 B1
6761734 Suhr Jul 2004 B1
6761735 Eberhardt et al. Jul 2004 B1
6764494 Menz et al. Jul 2004 B1
6764508 Roehe et al. Jul 2004 B1
6764509 Chinn et al. Jul 2004 B1
6764510 Vidlund et al. Jul 2004 B1
6767362 Schreck Jul 2004 B1
6769434 Liddicoat et al. Aug 2004 B1
6770083 Seguin Aug 2004 B1
6780200 Jansen Aug 2004 B1
6786924 Ryan et al. Sep 2004 B1
6786925 Schoon et al. Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B1
6790231 Liddicoat et al. Sep 2004 B1
6793673 Kowalsky et al. Sep 2004 B1
6797000 Simpson et al. Sep 2004 B1
6797001 Mathis et al. Sep 2004 B1
6797002 Spence et al. Sep 2004 B1
6802860 Cosgrove et al. Oct 2004 B1
6805710 Bolling et al. Oct 2004 B1
6805711 Quijano et al. Oct 2004 B1
6810882 Langberg et al. Nov 2004 B1
6821297 Snyders Nov 2004 B1
6824562 Mathis et al. Nov 2004 B1
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6837902 Nguyen et al. Jan 2005 B1
6840246 Downing Jan 2005 B1
6840957 DiMatteo et al. Jan 2005 B1
6846324 Stobie Jan 2005 B1
6846325 Liddicoat Jan 2005 B1
6858039 McCarthy Feb 2005 B1
20010021872 Bailey et al. Sep 2001 A1
20010039450 Pavenik et al. Nov 2001 A1
20020052651 Myers et al. May 2002 A1
20030023300 Bailey et al. Jan 2003 A1
20030069635 Cartledge et al. Apr 2003 A1
20030069646 Stinson Apr 2003 A1
20030130726 Thorpe et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030229394 Ogle et al. Dec 2003 A1
20030229395 Cox Dec 2003 A1
20030233142 Morales et al. Dec 2003 A1
20030236568 Hojeibane et al. Dec 2003 A1
20030236569 Mathis et al. Dec 2003 A1
20040002719 Oz et al. Jan 2004 A1
20040003819 St. Goar et al. Jan 2004 A1
20040010305 Alferness et al. Jan 2004 A1
20040015230 Moll et al. Jan 2004 A1
20040015232 Shu et al. Jan 2004 A1
20040015233 Jansen Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040019377 Taylor et al. Jan 2004 A1
20040019378 Hlavka et al. Jan 2004 A1
20040024447 Haverich Feb 2004 A1
20040024451 Johnson et al. Feb 2004 A1
20040024452 Kruse et al. Feb 2004 A1
20040030321 Fangrow, Jr. Feb 2004 A1
20040030381 Shu Feb 2004 A1
20040030382 St. Goar et al. Feb 2004 A1
20040030405 Carpentier et al. Feb 2004 A1
20040034380 Woolfson et al. Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040039442 St. Goar et al. Feb 2004 A1
20040039443 Solem et al. Feb 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040044365 Bachman Mar 2004 A1
20040044403 Bischoff et al. Mar 2004 A1
20040049207 Goldfarb et al. Mar 2004 A1
20040049211 Tremulis et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059351 Eigler et al. Mar 2004 A1
20040059411 Strecker Mar 2004 A1
20040059412 Lytle, IV et al. Mar 2004 A1
20040060161 Leal et al. Apr 2004 A1
20040073301 Donlon et al. Apr 2004 A1
20040073302 Rourke et al. Apr 2004 A1
20040078072 Tu et al. Apr 2004 A1
20040078074 Anderson et al. Apr 2004 A1
20040082910 Constantz et al. Apr 2004 A1
20040082923 Field Apr 2004 A1
20040082991 Nguyen et al. Apr 2004 A1
20040087975 Lucatero et al. May 2004 A1
20040088045 Cox May 2004 A1
20040088046 Speziali May 2004 A1
20040092858 Wilson et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093070 Hojeibane et al. May 2004 A1
20040093080 Helmus et al. May 2004 A1
20040097979 Svanidze et al. May 2004 A1
20040098098 McGuckin, Jr. et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040102839 Cohn et al. May 2004 A1
20040102840 Solem et al. May 2004 A1
20040102842 Jansen May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040106990 Spence et al. Jun 2004 A1
20040106991 Hopkins et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122448 Levine Jun 2004 A1
20040122512 Navia et al. Jun 2004 A1
20040122513 Navia et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040122515 Chu Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040127980 Kowalsky et al. Jul 2004 A1
20040127981 Rahdert et al. Jul 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040133220 Lashinski et al. Jul 2004 A1
20040133267 Lane Jul 2004 A1
20040133273 Cox Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040138744 Lashinski et al. Jul 2004 A1
20040138745 Macoviak et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148019 Vidlund et al. Jul 2004 A1
20040148020 Vidlund et al. Jul 2004 A1
20040153052 Mathis Aug 2004 A1
20040153146 Lashinski et al. Aug 2004 A1
20040153147 Mathis Aug 2004 A1
20040158321 Reuter et al. Aug 2004 A1
20040162610 Liska et al. Aug 2004 A1
20040167539 Keuhn et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040172046 Hlavka et al. Sep 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040176840 Langberg et al. Sep 2004 A1
20040181238 Zarbatany et al. Sep 2004 A1
20040186444 Daly et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186561 McGuckin, Jr. et al. Sep 2004 A1
20040186563 Iobbi Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040193191 Starksen et al. Sep 2004 A1
20040193253 Thorpe et al. Sep 2004 A1
20040193260 Alferness et al. Sep 2004 A1
20040199155 Mollenauer Oct 2004 A1
20040199183 Oz et al. Oct 2004 A1
20040199191 Schwartz Oct 2004 A1
20040204758 Eberhardt et al. Oct 2004 A1
20040206363 McCarthy et al. Oct 2004 A1
20040210240 Saint Oct 2004 A1
20040210301 Obermiller Oct 2004 A1
20040210303 Sedransk Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210305 Shu et al. Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220654 Mathis et al. Nov 2004 A1
20040220657 Nieminen et al. Nov 2004 A1
20040225322 Garrison et al. Nov 2004 A1
20040225344 Hoffa et al. Nov 2004 A1
20040225348 Case et al. Nov 2004 A1
20040225352 Osborne et al. Nov 2004 A1
20040225353 McGuckin, Jr. et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040225356 Frater Nov 2004 A1
20040230117 Tosaya et al. Nov 2004 A1
20040230297 Thornton Nov 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040236418 Stevens Nov 2004 A1
20040236419 Milo Nov 2004 A1
20040243153 Liddicoat et al. Dec 2004 A1
20040243219 Fischer et al. Dec 2004 A1
20040243227 Starksen et al. Dec 2004 A1
20040243228 Kowalsky et al. Dec 2004 A1
20040243230 Navia et al. Dec 2004 A1
20040249452 Adams et al. Dec 2004 A1
20040254600 Zarbatany et al. Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260276 Rudko et al. Dec 2004 A1
20040260317 Bloom et al. Dec 2004 A1
20040260322 Rudko et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20040267357 Allen et al. Dec 2004 A1
20050004583 Oz et al. Jan 2005 A1
20050004667 Swinford et al. Jan 2005 A1
20050010285 Lambrecht et al. Jan 2005 A1
20050010287 Macoviak et al. Jan 2005 A1
20050015112 Cohn et al. Jan 2005 A1
20050021056 St. Goar et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050027261 Weaver et al. Feb 2005 A1
20050027348 Case et al. Feb 2005 A1
20050027351 Reuter et al. Feb 2005 A1
20050027353 Alferness et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050033419 Alferness et al. Feb 2005 A1
20050033446 Deem et al. Feb 2005 A1
20050038506 Webler et al. Feb 2005 A1
20050038507 Alferness et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050043792 Solem et al. Feb 2005 A1
Foreign Referenced Citations (81)
Number Date Country
0732087 Sep 1996 EP
0856300 Aug 1998 EP
2728457 Jun 1996 FR
WO 0067679 Nov 2000 WO
WO 0119285 Mar 2001 WO
WO 0154625 Aug 2001 WO
WO 0156500 Aug 2001 WO
WO 0241764 May 2002 WO
WO 2004019825 Mar 2004 WO
WO 2004021893 Mar 2004 WO
WO 2004023980 Mar 2004 WO
WO 2004030568 Apr 2004 WO
WO 2004030569 Apr 2004 WO
WO 2004030570 Apr 2004 WO
WO 2004032724 Apr 2004 WO
WO 2004032796 Apr 2004 WO
WO 2004037128 May 2004 WO
WO 2004037317 May 2004 WO
WO 2004039432 May 2004 WO
WO 2004043265 May 2004 WO
WO 2004043273 May 2004 WO
WO 2004043293 May 2004 WO
WO 2004045370 Jun 2004 WO
WO 2004045378 Jun 2004 WO
WO 2004045463 Jun 2004 WO
WO 2004047677 Jun 2004 WO
WO 2004060217 Jul 2004 WO
WO 2004060470 Jul 2004 WO
WO 2004062725 Jul 2004 WO
WO 2004066803 Aug 2004 WO
WO 2004066826 Aug 2004 WO
WO 2004069287 Aug 2004 WO
WO2004075789 Sep 2004 WO
WO2004080352 Sep 2004 WO
WO2004082523 Sep 2004 WO
WO2004082527 Sep 2004 WO
WO2004082528 Sep 2004 WO
WO2004082536 Sep 2004 WO
WO2004082537 Sep 2004 WO
WO2004082538 Sep 2004 WO
WO2004082757 Sep 2004 WO
WO 2004084746 Oct 2004 WO
WO 2004084770 Oct 2004 WO
WO 2004089246 Oct 2004 WO
WO 2004089250 Oct 2004 WO
WO 2004089253 Oct 2004 WO
WO 2004091449 Oct 2004 WO
WO 2004091454 Oct 2004 WO
WO 2004093638 Nov 2004 WO
WO 2004093726 Nov 2004 WO
WO 2004093728 Nov 2004 WO
WO 2004093730 Nov 2004 WO
WO 2004093745 Nov 2004 WO
WO 2004093935 Nov 2004 WO
WO 2004096100 Nov 2004 WO
WO 2004103222 Dec 2004 WO
WO 2004103223 Dec 2004 WO
WO 2004105584 Dec 2004 WO
WO 2004105651 Dec 2004 WO
WO 2004112582 Dec 2004 WO
WO 2004112585 Dec 2004 WO
WO 2004112643 Dec 2004 WO
WO 2004112652 Dec 2004 WO
WO 2004112657 Dec 2004 WO
WO 2004112658 Dec 2004 WO
WO 2005000152 Jan 2005 WO
WO 2005002424 Jan 2005 WO
WO 2005002466 Jan 2005 WO
WO 2005004753 Jan 2005 WO
WO 2005007017 Jan 2005 WO
WO 2005007018 Jan 2005 WO
WO 2005007036 Jan 2005 WO
WO 2005007037 Jan 2005 WO
WO 2005009285 Feb 2005 WO
WO 2005009286 Feb 2005 WO
WO 2005009505 Feb 2005 WO
WO 2005009506 Feb 2005 WO
WO 2005011473 Feb 2005 WO
WO 2005011534 Feb 2005 WO
WO 2005011535 Feb 2005 WO
WO 2005013860 Feb 2005 WO
Related Publications (1)
Number Date Country
20040230297 A1 Nov 2004 US
Continuations (1)
Number Date Country
Parent 10115557 Apr 2002 US
Child 10873052 US